EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY 4.0

Establishing a Quantitative Framework for Combined Oral Contraceptives: Evaluating the Impact of Drug–Drug Interactions on Exposure and Clinical (Surrogate) Efficacy Endpoints

Dain Chun iD, Huili Chen iD, Brian Cicali iD, Serge Guzy iD, Joachim Hoechel iD, Tianze Jiao iD, Valvanera Vozmediano iD, Stephan Schmidt iD

The Journal of Clinical Pharmacology · 2025

DOI: 10.1002/jcph.70063 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift The Journal of Clinical Pharmacology, 2025. Verfasst von Dain Chun und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, FL, USA. Hauptthemen laut MEDLINE: Contraceptives, Oral, Combined, Models, Biological. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gates Foundation, Bill & Melinda Gates Foundation, Bill and Melinda Gates Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

According to the FDA Guidance for Industry on Clinical Drug Interaction (DDI) Studies with Combined Oral Contraceptives (COCs), sponsors are expected to conduct dedicated clinical DDI studies if in vitro findings suggest weak or moderate CYP3A induction, while concomitant use of COCs with strong inducers should be avoided. The guidance further suggests that a negative DDI result for drospirenone (DRSP) may be extrapolated to other progestins that are less sensitive to CYP3A modulation, such as levonorgestrel (LNG). This approach assumes that DDI‐mediated changes in exposure directly translate into clinical efficacy across progestins. To evaluate the validity of this assumption, we established a quantitative link between dose, exposure, and response (Pearl Index [PI] and ovulation rate [OR]) via an integrated model‐based meta‐analysis, physiologically based pharmacokinetic, and pharmacokinetic/pharmacodynamic (PK/PD) modeling and simulation approach using data from 51 clinical studies in 36,040 women receiving LNG or DRSP. COCs containing LNG and DRSP were selected because they represent clinically relevant progestins at the lower and the upper end of the fraction metabolized via CYP3A4. The results of our analysis show a moderate correlation (Pearson's r = 0.52, 95% CI 0.46‐0.58, P < 0.001) between PI and OR, which enables the use of OR as an ethically measurable endpoint, even at subtherapeutic doses/exposures, to predict efficacy outcomes. They further show that DDI‐induced changes in exposure do not directly translate into clinical response. Therefore, DDIs with COCs should be interpreted in a PK/PD rather than a PK‐only context. The quantitative framework developed in this study can serve as the scientific basis to do so.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Contraceptives, Oral, CombinedModels, BiologicalHumansFemaleDrug InteractionsLevonorgestrelAndrostenesCytochrome P-450 CYP3AOvulationAdultProgestinsCytochrome P-450 CYP3A Inducers

Stichwörter der Autor:innen

combined oral contraceptivesdrospirenonedrug–drug interactionslevonorgestrelmodel‐based meta‐analysisoperational model of agonismpharmacokinetics/pharmacodynamicsphysiologically based pharmacokinetics

Substanzen

Contraceptives, Oral, CombinedLevonorgestreldrospirenoneAndrostenesCytochrome P-450 CYP3AProgestinsCytochrome P-450 CYP3A Inducers

Autor:innen und Institutionen

  • Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, FL, USA.
  • Pop-Pharm Pharmacometrics Service, Albany, CA, USA.
  • Bayer AG, Berlin, Germany.
  • Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL, USA.
  • Model Informed Development, CTI Laboratories, Covington, KY, USA.

ORCID-Profile: Dain Chun, Huili Chen, Brian Cicali, Serge Guzy, Joachim Hoechel, Tianze Jiao, Valvanera Vozmediano, Stephan Schmidt

Förderung

  • Gates Foundation
  • Bill & Melinda Gates Foundation
  • Bill and Melinda Gates Foundation

Zitieren

APA

Chun, D., Chen, H., Cicali, B., Guzy, S., Hoechel, J., Jiao, T., Vozmediano, V., & Schmidt, S. (2025). Establishing a Quantitative Framework for Combined Oral Contraceptives: Evaluating the Impact of Drug–Drug Interactions on Exposure and Clinical (Surrogate) Efficacy Endpoints. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.70063

Vancouver

Chun D, Chen H, Cicali B, Guzy S, Hoechel J, Jiao T, et al. Establishing a Quantitative Framework for Combined Oral Contraceptives: Evaluating the Impact of Drug–Drug Interactions on Exposure and Clinical (Surrogate) Efficacy Endpoints. The Journal of Clinical Pharmacology. 2025. doi:10.1002/jcph.70063

BibTeX
@article{Chun2025,
  author = {Chun, Dain and Chen, Huili and Cicali, Brian and Guzy, Serge and Hoechel, Joachim and Jiao, Tianze and Vozmediano, Valvanera and Schmidt, Stephan},
  title = {Establishing a Quantitative Framework for Combined Oral Contraceptives: Evaluating the Impact of Drug–Drug Interactions on Exposure and Clinical (Surrogate) Efficacy Endpoints},
  journal = {The Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1002/jcph.70063}
}
Kostenlos starten →